回复彭宁顿，T.E.；汤普森，J.F. 《黑色素瘤前哨淋巴结活检仍是一种有价值的临床工具》。对“迪克森等人。2024年原发性皮肤黑色素瘤的管理。2024年，，1607”的评论
Reply to Pennington, T.E.; Thompson, J.F. Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on "Dixon et al. Primary Cutaneous Melanoma-Management in 2024. 2024, , 1607".
作者信息
Dixon Anthony Joseph, Sladden Michael, Zouboulis Christos C, Popescu Catalin M, Nirenberg Alexander, Steinman Howard K, Longo Caterina, Dixon Zoe Lee, Thomas Joseph Meirion
机构信息
Department of Research, Australasian College of Cutaneous Oncology, Docklands, VIC 3008, Australia.
Research, American Osteopathic College of Dermatology, Kirksville, MO 63501, USA.
出版信息
J Clin Med. 2025 Jan 2;14(1):216. doi: 10.3390/jcm14010216.
Abstract
We note with interest the commentary by Pennington and Thompson (P&T) regarding our detailed update on the management of primary cutaneous melanoma in 2024 [...].
摘要
我们饶有兴趣地注意到彭宁顿和汤普森（P&T）对我们2024年原发性皮肤黑色素瘤管理详细更新的评论[……]。
相似文献
1
Reply to Pennington, T.E.; Thompson, J.F. Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on "Dixon et al. Primary Cutaneous Melanoma-Management in 2024. 2024, , 1607".回复彭宁顿，T.E.；汤普森，J.F. 《黑色素瘤前哨淋巴结活检仍是一种有价值的临床工具》。对“迪克森等人。2024年原发性皮肤黑色素瘤的管理。2024年，，1607”的评论
J Clin Med. 2025 Jan 2;14(1):216. doi: 10.3390/jcm14010216.
2
Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on Dixon et al. Primary Cutaneous Melanoma-Management in 2024. 2024, , 1607.黑色素瘤前哨淋巴结活检仍是一项有价值的临床工具。对 Dixon 等人《2024 年原发性皮肤黑色素瘤的管理》的评论。2024 年，，1607。
J Clin Med. 2025 Jan 2;14(1):215. doi: 10.3390/jcm14010215.
3
Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.静脉注射大剂量干扰素 alfa-2b 治疗可减少黑色素瘤患者循环中的调节性 T 细胞。
Clin Exp Metastasis. 2012 Oct;29(7):801-5. doi: 10.1007/s10585-012-9504-2. Epub 2012 Jul 1.
4
When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the 'Australian guidelines for the management of cutaneous melanoma'.对于原发性黑色素瘤患者，何时进行前哨淋巴结活检？《澳大利亚皮肤黑色素瘤管理指南》更新版
Australas J Dermatol. 2017 Nov;58(4):274-277. doi: 10.1111/ajd.12662. Epub 2017 Jul 17.
5
Reply to Schimmelbusch, K.J.; Collison, F.T. Comment on "Rosa et al. Optic Nerve Drusen Evaluation: A Comparison between Ultrasound and OCT. 2022, , 3715".回复施密尔布施，K.J.；科利森，F.T. 对“罗莎等人。视神经乳头 drusen 评估：超声与 OCT 的比较。2022 年，，3715”的评论。
J Clin Med. 2023 Sep 1;12(17):5697. doi: 10.3390/jcm12175697.
6
Reply to Kielb et al. Untapped Potential for Female Patients? Comment on "Lucà et al. Update on Management of Cardiovascular Diseases in Women. 2022, , 1176".回复基尔布等人。女性患者的未开发潜力？评《卢卡等人。女性心血管疾病管理的最新进展。2022年，，1176》
J Clin Med. 2022 May 30;11(11):3086. doi: 10.3390/jcm11113086.
7
Sentinel node identification by scintigraphic methods in cutaneous melanoma.通过闪烁显像法识别皮肤黑色素瘤中的前哨淋巴结
J Exp Clin Cancer Res. 2005 Jun;24(2):181-5.
8
Reply to Böning et al. Comment on "Ceruti et al. Temporal Changes in the Oxyhemoglobin Dissociation Curve of Critically Ill COVID-19 Patients. 2022, , 788".回复博宁等人。对“切鲁蒂等人。危重症COVID-19患者氧合血红蛋白解离曲线的时间变化。2022年，，788”的评论
J Clin Med. 2022 Aug 4;11(15):4547. doi: 10.3390/jcm11154547.
9
Sentinel lymph node biopsy in patients with clinical stage IIB/C cutaneous melanoma: A national cohort study.临床 IIB/C 期皮肤黑色素瘤患者前哨淋巴结活检：一项全国性队列研究。
J Am Acad Dermatol. 2022 Oct;87(4):754-760. doi: 10.1016/j.jaad.2022.04.025. Epub 2022 Apr 22.
10
Reply to: "Comment on 'Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma'".
J Am Acad Dermatol. 2018 Sep;79(3):e55-e56. doi: 10.1016/j.jaad.2018.05.018. Epub 2018 May 19.
本文引用的文献
1
BAUSSS biomarker improves melanoma survival risk assessment.BAUSSS生物标志物改善黑色素瘤生存风险评估。
J Eur Acad Dermatol Venereol. 2025 Apr;39(4):865-870. doi: 10.1111/jdv.20292. Epub 2024 Aug 31.
2
BAUSSS biomarker further validated as a key risk staging tool for patients with primary melanoma.BAUSSS生物标志物进一步验证为原发性黑色素瘤患者的关键风险分期工具。
J Eur Acad Dermatol Venereol. 2024 Sep;38(9):e779-e781. doi: 10.1111/jdv.19889. Epub 2024 Feb 20.
3
Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients.前哨淋巴结活检术在预测年轻和老年患者的黑色素瘤死亡率方面均不可靠。
J Eur Acad Dermatol Venereol. 2024 Apr;38(4):741-751. doi: 10.1111/jdv.19772. Epub 2024 Jan 3.
4
Online tools for predicting melanoma survival: Including sentinel node status as a variable improves prediction accuracy.
J Eur Acad Dermatol Venereol. 2024 Feb;38(2):e182-e184. doi: 10.1111/jdv.19524. Epub 2023 Oct 14.
5
Improved methodology in determining melanoma mortality and selecting patients for immunotherapy.
J Eur Acad Dermatol Venereol. 2023 Jul;37(7):e843-e845. doi: 10.1111/jdv.18951. Epub 2023 Feb 22.
6
Preoperative assessment of cutaneous melanoma thickness by multispectral dermoscopy.多光谱皮肤镜对皮肤黑色素瘤厚度的术前评估
Melanoma Res. 2023 Feb 1;33(1):84-86. doi: 10.1097/CMR.0000000000000862. Epub 2022 Dec 20.
7
Assessment of melanoma thickness based on dermoscopy images: an open, web-based, international, diagnostic study.基于皮肤镜图像的黑色素瘤厚度评估：一项开放、基于网络的国际诊断研究。
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2002-2007. doi: 10.1111/jdv.18436. Epub 2022 Jul 26.
8
Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable.
Br J Dermatol. 2022 Dec;187(6):997-998. doi: 10.1111/bjd.21712. Epub 2022 Jul 12.
9
Dermoscopy as a Tool for Estimating Breslow Thickness in Melanoma.皮肤镜检查在估计黑色素瘤 Breslow 厚度中的作用。
Actas Dermosifiliogr (Engl Ed). 2021 May;112(5):434-440. doi: 10.1016/j.ad.2020.11.015. Epub 2020 Nov 28.
10
Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor.前哨淋巴结活检术可提高黑色素瘤患者的分期准确性，尤其在结合原发灶的临床病理特征时。
Ann Oncol. 2021 Mar;32(3):375-383. doi: 10.1016/j.annonc.2020.11.015. Epub 2020 Nov 28.
Zotero 插件